Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2015

01-04-2015 | Breast Cancer (B Overmoyer, Section Editor)

Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments

Authors: Daniel G. Stover, Nikhil Wagle

Published in: Current Oncology Reports | Issue 4/2015

Login to get access

Abstract

Remarkable progress in sequencing technology over the past 20 years has made it possible to comprehensively profile tumors and identify clinically relevant genomic alterations. In breast cancer, the most common malignancy affecting women, we are now increasingly able to use this technology to help specify the use of therapies that target key molecular and genetic dependencies. Large sequencing studies have confirmed the role of well-known cancer-related genes and have also revealed numerous other genes that are recurrently mutated in breast cancer. This growing understanding of patient-to-patient variability at the genomic level in breast cancer is advancing our ability to direct the appropriate treatment to the appropriate patient at the appropriate time—a hallmark of “precision cancer medicine.” This review focuses on the technological advances that have catalyzed these developments, the landscape of mutations in breast cancer, the clinical impact of genomic profiling, and the incorporation of genomic information into clinical care and clinical trials.
Literature
1.
2.
3.
Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31:1806–14.CrossRef
4.
MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31:1815–24.CrossRef
5.
Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977;37:4669–71.PubMed
6.
Fisher B, Redmond C, Brown A, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med. 1981;305:1–6.CrossRefPubMed
7.
Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981;304:16–21.CrossRefPubMed
8.
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol : Off J Ame Soc Clin Oncol. 1999;17:1474–81.
9.
van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239–45.CrossRefPubMed
10.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.CrossRefPubMed
11.
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.CrossRefPubMed
12.
Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.CrossRefPubMedCentralPubMed
13.
Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418–23.CrossRefPubMedCentralPubMed
14.
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.CrossRefPubMed
15.
van ‘t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRefPubMed
16.
van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature. 2008;452:564–70.CrossRef
17.
Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42.CrossRefPubMed
18.
19.
Wagle N, Van Allen EM, Treacy DJ, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014;4:61–8.CrossRefPubMedCentralPubMed
20.
Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. The New England journal of medicine 2014.
21.
22.
23.
Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer. The New England journal of medicine 2014.
24.
Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.CrossRefPubMed
25.
26.
Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466:869–73.CrossRefPubMed
27.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMed
28.
Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31:1097–104.CrossRef
29.•
Ali SM, Alpaugh RK, Buell JK, et al. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014;14:e14–6. In this case report, a patient with advanced HER2+ inflammatory breast cancer, that had developed resistance to HER2-targeted therapy was found by genomic profiling to have an L858R base substitution in EGFR, a well-known activating mutation in non-small cell lung cancer. Treatment with erlotinib, an EGFR-targeted therapy approved in NSCLC, was effective, with an 8-month period of cancer regression as well as symptomatic improvement. This case report is an example of how genomic profiling can identify targeted therapies that otherwise might not be considered for patients with breast cancer.CrossRefPubMed
30.
Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685–96.CrossRefPubMed
31.
Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146–58.CrossRefPubMedCentralPubMed
32.
33.
Johnson DB, Dahlman KH, Knol J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014;19:616–22.CrossRefPubMedCentralPubMed
34.
MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn : JMD. 2014;16:660–72.CrossRefPubMed
35.
Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31:1825–33.CrossRef
36.
Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2:82–93.CrossRefPubMedCentralPubMed
37.
Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.CrossRef
38.
Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486:400–4.PubMedCentralPubMed
39.
Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486:395–9.PubMed
40.
Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486:405–9.CrossRefPubMedCentralPubMed
41.
Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486:353–60.PubMedCentralPubMed
42.
43.
Natrajan R, Mackay A, Lambros MB, et al. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. J Pathol. 2012;227:29–41.CrossRefPubMed
44.
De Brot M, Andrade V, Morrogh M, et al. Novel mutations in lobular carcinoma in situ (LCIS) as uncovered by targeted parallel sequencing. Cancer research 2012;72
45.
Lim WK, Ong CK, Tan J, et al. Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet. 2014;46:877–80.CrossRefPubMed
46.
Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.PubMedCentralPubMed
47.
48.
Blackwell K, Hamilton E, Marcom P, et al. Abstract S4-03: Exome sequencing reveals clinically actionable mutations in the pathogenesis and metastasis of triple negative breast cancer. Cancer Res. 2013;73:S4–S03.CrossRef
49.
Wagle N, Lin NU, Richardson AL, et al. Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003. ASCO Meet Abstr. 2014;32:536.
50.
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.CrossRefPubMed
51.
Vaz-Luis I, Zeghibe CA, Frank ES, et al. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013;142:203–9.CrossRefPubMedCentralPubMed
52.
Andre F, Bachelot TD, Campone M, et al. Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01). ASCO Meet Abstr. 2013;31:511.
53.•
Andre F, Bachelot T, Commo F, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15:267–74. The SAFIR01 study evaluated 423 patients with metastatic breast cancer, identifying a targetable genomic alteration in 195 patients (46%). While only a small subset – 55 patients (13%) received ‘personalized’ therapy, this trial provides a proof of concept for incorporating genomic analyses into clinical studies.CrossRefPubMed
54.
Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra21.CrossRef
55.•
Zardavas D, Maetens M, Irrthum A, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer 2014. The AURORA initiative is a prospective study that will perform next generation sequencing for a panel of cancer-related genes on tumour tissue and blood samples from patients with meastatic breast cancer, then follow them longitudinally. This multi-national study hopes to direct patients into clinical trials based on their genomic characteristics, while also collecting information about long-term outcomes for this cohort
56.
Van Allen EM, Wagle N, Stojanov P, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20:682–8.CrossRefPubMedCentralPubMed
57.
Conley BA, Doroshow JH. Molecular Analysis for Therapy Choice: NCI MATCH. Semin Oncol. 2014;41:297–9.CrossRefPubMed
58.
Everett JN, Gustafson SL, Raymond VM. Traditional roles in a non-traditional setting: genetic counseling in precision oncology. J Genet Couns. 2014;23:655–60.CrossRefPubMed
59.
Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. JClin Oncol : Off J Am Soc Clin Oncol. 2013;31:1834–41.CrossRef
60.
Slosberg ED, Kang B, Beck JT, et al. The signature program, a series of tissue-agnostic, mutation-specific signal finding trials. ASCO Meet Abstr. 2014;32:TPS2646.
61.
Balko JM, Giltnane JM, Wang K, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4:232–45.CrossRefPubMedCentralPubMed
62.
Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Cli Cancer Res : Off J Am Assoc Cancer Res. 2014;20:1757–67.CrossRef
63.
Li S, Shen D, Shao J, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–30.CrossRefPubMed
64.•
Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–51. These two studies demonstrated mutations in the estrogen receptor gene, ESR1, as a novel mechanism of resistance to hormonal therapy in breast cancer. This observation illuminates the importance of genomic characterization not just for potential susceptibilities but also resistance to therapy.CrossRefPubMedCentralPubMed
65.•
Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45:1439–45. These two studies demonstrated mutations in the estrogen receptor gene, ESR1, as a novel mechanism of resistance to hormonal therapy in breast cancer. This observation illuminates the importance of genomic characterization not just for potential susceptibilities but also resistance to therapy.CrossRefPubMedCentralPubMed
66.
Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345:216–20.CrossRefPubMed
67.
Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G mutation in estrogen receptor-alpha: A novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013;73:6856–64.CrossRefPubMed
68.
69.
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32.CrossRef
70.
Wagle N, Grabiner BC, Van Allen EM, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4:546–53.CrossRefPubMedCentralPubMed
71.
Wagle N, Grabiner BC, Van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371:1426–33.CrossRefPubMed
72.
Abrams J, Conley B, Mooney M, et al. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting 2014:71–6
73.
Al-Ahmadie H, Iyer G, Hohl M, et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov. 2014;4:1014–21.CrossRefPubMedCentralPubMed
74.
75.
Rath MG, Masciari S, Gelman R, et al. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Res Treat. 2013;139:193–8.CrossRefPubMedCentralPubMed
76.•
Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA. 2014;311:1035–45. An evaluation of whole genome sequencing on 12 patients reveals the challenges of sequencing the whole genome - incomplete coverage and low reproducibility of known disease-associated genetic variants with difficulty determining what findings to convey to patients. This supports a multiplexed, targeted sequencing approach of actionable genes for tumors rather than whole genome sequencing.CrossRefPubMed
77.
78.
Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461:809–13.CrossRefPubMed
79.
80.
Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225–33.CrossRefPubMed
81.
82.
Navin N, Kendall J, Troge J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–4.CrossRefPubMed
83.
84.
85.
86.
87.
88.
Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32:479–84.CrossRefPubMedCentralPubMed
89.
Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–22.CrossRefPubMed
90.
91.
Dawson SJ, Rosenfeld N, Caldas C. Circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;369:93–4.CrossRefPubMed
92.
Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199–209.CrossRefPubMed
93.
Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014.
94.
van Rooij N, van Buuren MM, Philips D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31:e439–42.CrossRef
Metadata
Title
Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments
Authors
Daniel G. Stover
Nikhil Wagle
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2015
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-015-0438-0

Other articles of this Issue 4/2015

Current Oncology Reports 4/2015 Go to the issue

Evolving Therapies (R Bukowski, Section Editor)

Activin Receptor Inhibitors—Dalantercept

Gastrointestinal Cancers (B Czito, Section Editor)

Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?

Gynecologic Cancers (NS Reed, Section Editor)

Adenocarcinoma of the Cervix: Should We Treat It Differently?

Gastrointestinal Cancers (BG Czito, Section Editor)

Contemporary Surgical Options for Metastatic Colorectal Cancer

Gynecologic Cancers (NS Reed, Section Editor)

Radical Surgery in Ovarian Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits